Mantle Cell Lymphoma
News
Bendamustine-rituximab shines in frontline treatment of MCL, iNHL
Long-term follow-up data from the BRIGHT study support bendamustine plus rituximab as a frontline treatment option in mantle cell lymphoma and...
Conference Coverage
Dual-targeted CAR T shows ‘clinical signal’ in NHL
HOUSTON – Due to local manufacturing of the CAR T-cell therapy, most patients were able to receive fresh, rather than cryopreserved, product.
News
Adding palbociclib upped responses in previously treated MCL
The positive response means that the combination of ibrutinib and palbociclib will continue to be tested in a phase 2 trial.
News
Daratumumab disappoints in non-Hodgkin lymphoma trial
The drug, used in multiple myeloma, was safe but ineffective in patients with non-Hodgkin lymphoma.
News
Combo appears to overcome aggressive L-NN-MCL
Two case studies highlight the role that P53 gene status plays in prognosis and treatment.
News
FDA grants BI-1206 orphan designation for MCL
BI-1206 is under investigation in a phase 1/2a study.
News
Autologous transplant linked to PFS benefit in MCL
No overall survival benefit was detected in this retrospective study, in contrast to a previous analysis.
News
Zanubrutinib receives breakthrough designation for MCL
The Bruton’s tyrosine kinase inhibitor was evaluated in a phase 2 trial.
News
Adding umbralisib to ibrutinib produced responses in MCL, CLL
The doublet regimen “is the first successful combination for two drugs targeting B-cell blockade.”
Conference Coverage
Lenalidomide maintenance improves MCL survival after ASCT
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.